Paul W. Armstrong
Dr. Armstrong is Professor in the Department of Medicine (Cardiology) at the University of Alberta, Edmonton, Alta.
Correspondence to: Dr. Paul W. Armstrong, 2-51 Medical Sciences Building, University of Alberta, Edmonton AB T6G 2H7; [email protected]
The first article in a series on new advances in the management of acute coronary syndromes appears on page 1309 of this issue.1 There have been major advances in our understanding of the pathophysiology of these increasingly common, important and challenging syndromes over the last decade.2 Along with these advances has been the realization that patients presenting with acute coronary syndromes constitute a heterogeneous group, with different prognostic probabilities for the main outcomes (death, recurrent myocardial infarction and refractory ischemia) on the one hand and a more benign long-term outcome on the other.3,4
It seems especially timely to address the problem of acute coronary syndromes, because clinical practitioners in family medicine, internal medicine and emergency medicine as well as those in cardiovascular medicine and surgery face increased numbers of such patients who present with chest pain. These patients are often well informed, and many have increased expectations based on their positive experiences with prior medical therapy or revascularization. This phenomenon occurs at a time when there are a host of new pharmacologic therapies and interventional strategies available. Together they form an impressive and complex array of choices, which carry with them major economic implications for our health care system. Moreover, the intense pressure on Canadian emergency departments coupled with a marked reduction in the number of hospital beds across the country creates a compelling need to make rapid and cost-effective decisions that serve the care of these patients well.
Hence, in the first article in this series, on facilitating and matching risk factors with therapeutic strategies, David Fitchett and colleagues alert readers to a systematic process of risk evaluation when patients first present with an acute coronary syndrome. They also emphasize opportunities that exist for continuously evaluating risk during the first few hours of observation and beyond. Incorporating simple clinical data and novel diagnostic biochemical markers facilitates this task.5
Fitchett and colleagues provide a useful platform from which to interpret subsequent articles in the series, which will address the following topics: the development of low-molecular-weight heparins and other antithrombin agents, which offer useful advantages over conventional unfractionated heparin;6 the emergence of new compounds that inhibit platelet aggregation, thereby addressing the platelet-rich component of coronary thrombi and the recently recognized role of platelet emboli to the distal coronary vascular tree;7 new pharmacologic approaches to coronary fibrinolysis for acute myocardial infarction with ST-segment elevation, which, coupled with antiplatelet and antithrombin therapy, are creating a new treatment paradigm (primary mechanical intervention with percutaneous transluminal coronary angioplasty and its effectiveness in patients who do not respond to pharmacologic intervention has made significant strides as well8); and the remarkable advances in catheter technology and the advent of intracoronary stenting. A particular challenge with this last topic is the optimal patient selection and timing of the interventions as well as their appropriate interface with the new drug therapies.9
Canada has made significant contributions to the basic and clinical research of a number of the treatment advances discussed in this series. This welcome occurrence, coupled with the participation of not only academic centres but also many community hospitals across the country, has resulted in a growing appreciation of our role in key international collaborative endeavours.
We hope that this series will not only be informative about this rapidly changing area of medicine but that it will also generate interest and dialogue and result in improved patient care.
Footnotes
Competing
interests: None declared.
References
The RNA-binding protein, TB-RBP, is the mouse
homologue of translin, a recombination protein associated with
chromosomal translocations
The mouse RNA-binding protein, TB-RBP, suppresses translation in vitro
and attaches mRNAs to microtubules by binding to conserved elements
in the 3
untranslated regions of specific mRNAs. We have now purified TB-RBP
from testicular and brain cytoplasmic extracts and cloned its cDNA.
We find that the mouse TB-RBP cDNAs contain an open reading frame of
228 amino acids with a leucine zipper domain within its C
terminus, a transmembrane helix, and a group of putative
phosphorylation sites. TB-RBP shows 99% identity to the human
protein, translin, a recombination hotspot-binding protein
associated with chromosomal translocations [Aoki, K., Suzuki, K.,
Sugano, T., Tasaka, T., Nakahara, K., Kuge, O., Omori, A. & Kasai,
M. (1995) Nat. Genet. 10, 167-174]. As shown for translin,
TB-RBP also binds to single-stranded DNAs containing a broad range of
consensus sequences, many of which are similar to the Y and H
RNA-binding sequences. Recombinant TB-RBP was synthesized and an
antiserum was prepared against the recombinant protein. The identity
between translin and TB-RBP was confirmed by demonstrating that
immunoprecipitation of TB-RBP from testicular extracts abolished formation
of the RNA-TB-RBP complex. Based upon its DNA binding to target
sequences in clustered breakpoint regions, we propose that TB-RBP
may be involved in DNA recombination or DNA repair in male germ
cells.
RNA-protein interactions modulate gene expression at many different posttranscriptional
levels (reviewed in refs. 1-3). In addition
to mRNA processing and transport from the nucleus to the cytoplasm,
RNA-binding proteins facilitate mRNA translation, stability, and
subcellular localization. In many cases, these regulatory proteins
recognize cis-acting sequences within the 5
or 3
untranslated regions (UTRs) of mRNAs (4-8). Such
interactions are especially common during oogenesis, where
RNA-binding proteins help mask, accumulate, localize, and ultimately
translate many "maternal" mRNAs (reviewed in refs. 4, 9, and 10).
In the testis, an analogous situation exists for "paternal" mRNAs
in the differentiating male germ cells. This occurs because many
sperm-specific proteins are synthesized after cessation of transcription
in the haploid phase of spermatogenesis. This necessitates posttranscriptional
regulation for many mRNAs, which are transcribed in meiotic or
postmeiotic cells and undergo spatial and temporal translation at
specific developmental times (reviewed in refs. 4 and 11-14). The
importance of the 3
UTR for translational control in mRNAs encoding proteins such as the
sperm nuclear protein, protamine 1, has been well documented in
"in vitro" studies and in transgenic mice (15-18).
We have previously identified a phosphoprotein, testis brain-RNA-binding
protein (TB-RBP), that specifically binds to highly conserved
cis-acting sequences in the 3
UTRs of a number of testicular and brain mRNAs, including protamines
1 and 2 (15,
19). TB-RBP represses
the in vitro translation of mRNA constructs containing specific
conserved sequences of protamine 2 (15) and also binds
mRNAs encoding proteins, such as tau and myelin basic protein, to
microtubules (16,
20).
To begin to define the mechanisms of action of TB-RBP, we have isolated
TB-RBP from testicular and brain cytoplasmic extracts and cloned its
cDNA from a mouse testis cDNA library. We report here that TB-RBP is
identical to the DNA-binding protein, translin, a protein that binds
to a group of single-stranded DNA sequences present at breakpoint
junctions of chromosomal translocations (21).
Preparation of Testicular and Brain Extracts.
Testicular and brain cytoplasmic extracts were prepared from sexually mature
male CD-1 mice (Charles River Breeding Laboratories) by a modified
procedure of Kwon and Hecht (15) and Han et
al. (20).
The testes were decapsulated, washed three times with buffer A
(10 mM Hepes, pH 7.6/1.5 mM MgCl2/10 mM KCl/0.5 mM DTT/0.5
mM phenylmethylsulfonyl flouride (PMSF)/0.5 µg/ml leupeptin/0.7 µg/ml
pepstatin/2 µg/ml aprotinin) and resuspended in buffer A to a final
volume of 0.5-1 g/ml. Testes were minced and homogenized in a Teflon
glass homogenizer on ice until most of the cells were lysed. The
homogenates were centrifuged for 15 min at 5,000 rpm in a
Sorvall SS-34 rotor to remove tissue debris, unbroken cells, and
nuclei. After 0.11 vol of buffer B (100 mM Hepes, pH 7.6/30 mM
MgCl2/100 mM KCl) was added to the supernatants, the solution was
centrifuged for 1 hr at 34,000 rpm in a Beckman SW 50.1 rotor.
The high-speed supernatants were either used immediately or stored at
70°C.
A similar protocol was followed to prepare brain cytosol extracts.
The protein concentration of supernatants ranged from 10 to
20 mg/ml.
Preparation of RNA Transcripts.
For RNA gel retardation assays, [32P]-labeled RNAs were
transcribed from a pGem 3Z plasmid containing transcript c (a
67 nucleotide insert containing the Y and H elements of the 3
UTR of mP2) (19).
Transcriptions were carried out with 20 units of SP6 polymerase,
60 µCi of [32P]CTP (3000 Ci/mmol;
1 Ci = 37 GBq; Amersham)/19 µm unlabeled CTP,
and 495 µm UTP, TTP, and ATP in a reaction volume of 20 µl. RNA
transcripts were purified as previously described (20).
For RNA affinity chromatography, transcript c was subcloned into the HindIII
and AvaI sites of the pSP64 poly(A) vector (Promega), generating
the construct pSP64-C. After linearizing pSP64-C with EcoRI,
SP6 polymerase was used to synthesize RNA containing transcript c
and 30 nucleotides of poly(A).
UV Crosslinking of RNA-Protein Complexes.
Gel retardation assays of RNA-protein complexes were carried out by the
method of Kwon and Hecht (19). For
UV-crosslinking, RNA-protein complexes were irradiated on ice in a
UV Stratalinker 1800 (Stratagene) with 254-nm, 8-W UV bulbs for
40 min, and resolved in 4% native polyacrylamide gels. The
RNA-protein complexes, identified by autoradiography, were cut from
the gels and digested with RNase T1 for 30 min at room
temperature. After mixing with SDS buffer (125 mM Tris·HCl, pH
6.8/0.1% SDS/1 mM EDTA), the gel slices were placed on top of an
SDS/15% polyacrylamide gel and electrophoresed to resolve the
UV-crosslinked RNA-protein complex (20).
Affinity Purification of TB-RBP.
TB-RBP was purified by a modification of the method of Gu and Hecht (22).
Polyadenylylated transcript c RNA was generated in vitro with
the SP6 MEGAscript kit (Ambion) using the EcoRI linearized
pSP64-C vector. To allow quantitation of RNA, a trace amount of [32P]CTP
was incorporated into the RNA transcripts. One milliliter of poly(U)
agarose beads (Pharmacia, type 6) was suspended in RNA-binding
buffer (25 mM Hepes, pH 7.5/100 mM KCl) and packed into a 15-ml
column. The polyadenylylated transcript c (200 µg in 3 ml
of RNA-binding buffer) was loaded over the column at 4°C and
recycled five times. The binding efficiency of the poly(A)+ RNA to
the poly(U) agarose beads was determined by monitoring the [32P]-labeled
RNA in the washes. After the RNA bound to the poly(U) agarose beads
was equilibrated with the extract buffer (1 vol buffer A plus
0.11 vol buffer B), 25 ml of testicular or brain extracts
(10-20 mg/ml) containing 60 units/ml RNasin and 5 mg/ml heparin
was mixed with the affinity beads at room temperature. To maximize
RNA-protein binding, the extract and RNA affinity beads were
incubated for 1 hr with gentle shaking. The beads were then
pelleted by centrifugation at 1,000 rpm (Beckman J2-21) for 5 min,
resuspended in 20 ml of washing buffer A (20 mM Hepes, pH
7.5/40 mM KCl/5 mg/ml heparin) and packed into a 15-ml column. The
column was washed with 20 ml washing buffer B (20 mM Hepes, pH
7.5/40 mM KCl/0.5% Nonidet P-40), 20 ml of washing buffer C (20 mM
Hepes, pH 7.5/40 mM KCl/40 µg/ml poly(ACU)/0.5% Nonidet P-40), and
20 ml of washing buffer D (20 mM Hepes, pH 7.5/40 mM KCl/5
mg/ml heparin). Bound protein fractions were step eluted with
2 ml of 0.5 M, 1.0 M, and 1.5 M KCl in 20 mM Hepes (pH
7.5). The eluted protein fractions were dialyzed against buffer E
(10 mM Hepes, pH 7.5/40 mM KCl/3 mM MgCl2/1 mM DTT/5%
glycerol/0.5 mM PMSF) at 4°C before being analyzed by SDS/PAGE and
RNA-binding assays.
Purification of TB-RBP by DEAE-Sepharose Chromatography.
The dialyzed protein fraction, containing the enriched TB-RBP from the RNA
affinity column, was applied to a column packed with 1.5 ml
DEAE-Sepharose 6B (Pharmacia) equilibrated with buffer E. After
the protein was loaded, the column was washed with 20 ml of buffer E
and then eluted with a step gradient of 100 mM, 300 mM,
500 mM, and 1,000 mM KCl in 10 mM Hepes (pH 7.5). After dialysis
against buffer E, aliquots of fractions were assayed for RNA-binding
activity and for protein purity by SDS/PAGE.
Determination of Partial Protein Sequence.
The protein fraction from the DEAE-Sepharose 6B column, containing the
highly enriched TB-RBP, was concentrated with a Centricon-30 filter
(Amicon) and aliquots were electrophoresed in SDS/12.5% PAGE.
Proteins were transferred from the polyacrylamide gel to a
polyvinylidene diflouride membrane with a Semi-Dry trans-Blot SD
(Bio-Rad) at 20 V for 1 hr at 4°C. One protein band, corresponding
to TB-RBP, was visualized by Ponceau S staining, cut out, and microsequenced
by the Department of Microchemistry of Harvard University.
Isolation and Analysis of TB-RBP cDNAs.
Two oligonucleotide primers, A (5-GTTGTACAGAGTTTAGAACA-3
)
and B (5
-GAGATGATCTTCCACATCCAGA-3
),
predicted from two peptide sequences of TB-RBP, were synthesized and
used for PCR amplification to generate a 306-bp TB-RBP cDNA
fragment. After confirming by sequencing that the cDNA encoded the
predicted amino acid sequence, the 306-bp cDNA was used as a probe
for cDNA library screening. Two mouse testis cDNA libraries, an
oligo(dT) primed
ZAP
II cDNA library (Stratagene) and a 5
-stretch
gt11
cDNA library (CLONTECH), were screened by plaque hybridization with
the 306-bp [32P]-labeled cDNA probe. Ten positive clones were
isolated and sequenced yielding most of the TB-RBP sequence. To
obtain the 5
terminus, a 280-bp TB-RBP cDNA was generated from a testicular cDNA
library constructed with the Marathon Race kit (CLONTECH) by PCR
amplification using an internal TB-RBP primer (5
-CCAATGCTCATGAAACCTGTAAT-3
)
and an adaptor primer.
Preparation of Recombinant TB-RBP.
To prepare recombinant TB-RBP, a cDNA encoding the entire open reading frame
of TB-RBP was amplified by PCR with the primers 5-GTGAATTCGCCACCATGTCTGTGAGCGA-3
and 5
-GCCCCGGGTAACTACAGAAAGAGGCA-3
.
The PCR product was cloned into the EcoRI and SmaI sites of
the prokaryotic expression vector pGEX-4T-1 (Pharmacia), fidelity
of amplification was confirmed by DNA sequencing, and TB-RBP was expressed
as a glutathione S-transferase (GST)-TB-RBP fusion protein in
Escherichia coli strain BL21. Transformants were grown in 2×YT medium
at 25°C for 3-4 hr to an optical density of 1.0, and the fusion
protein was induced with 0.1 mM isopropyl
-D-thiogalactoside for 4 hr. The
cells were harvested and the GST-TB-RBP was purified with the Bulk
GST Purification Module (Pharmacia). After thrombin cleavage, TB-RBP
was separated from GST with the Bulk GST Purification Module
(Pharmacia). From a one-liter culture, about 1 mg of TB-RBP was
obtained.
Production of Anti-TB-RBP Antibodies.
An affinity-purified rabbit anti-TB-RBP peptide antibody was prepared by
Quality Controlled Biochemicals (Hopkinton, MA) using the TB-RBP
peptide sequence of KNDSLRKRYDGLKYDV. A rabbit polyclonal anti-TB-RBP
antibody was raised against the recombinant TB-RBP protein by HRP
(Denver, PA).
Immunodepletion of TB-RBP and Western Blot Assay.
BSA-blocked protein A agarose beads (150 µl, 17% slurry) in 50 µl
Tris-buffered saline (TBS) were incubated with 50 µl pre-immune serum
or 50 µl anti-TB-RBP serum for 1 hr at 4°C. The beads were washed
four times with 1 ml of TBS containing 0.1% Nonidet P-40 and
0.25% BSA and then incubated with 50 µl of testicular cytosolic extract
(14 mg/ml) in a total volume of 150 µl diluted with TBS containing
0.1% Nonidet P-40. Incubations were carried out for 4 hr at 4°C.
After centrifugation for 2 min at 1,500 rpm, the supernatants
were collected and used for RNA gel shift and Western blot assays.
The pellets were assayed for TB-RBP by Western blotting.
For Western blotting, equal volumes (14 µl) of supernatant were
electrophoresed in SDS/10% polyacrylamide gels and the proteins were
transferred onto nitrocellulose membranes. The membranes were
blotted overnight with TBS containing 5% dry milk at 4°C, and then
incubated with the anti-TB-RBP peptide antibody (1:1,000) in TBS
containing 0.25% milk for 1.5 hr at room temperature (RT). After
washing, the membranes were incubated with protein A conjugated with
horseradish peroxidase and the TB-RBP was detected with the enhanced
chemiluminescence protocol (Amersham).
DNA Gel Shift Analysis.
One hundred nanograms of the oligonucleotide, Bcl-CL1
(GCCCTCCTGCCCTCCTTCCGCGGG) (21), was labeled at
its 5
end with [32P]ATP and T4 polynucleotide kinase. Unincorporated [32P]ATP
was removed by passage through a Chromaspin-10 column (CLONTECH). For
the DNA-binding assay, recombinant TB-RBP (50 ng) was incubated with
4 µg of poly(dI·dC) in 20 µl of binding buffer (20 mM Hepes,
pH 7.6/3 mM MgCl2/40 mM KCl/2 mM DTT/5% glycerol) at RT for 10
min. The [32P]labeled Bcl-CL1 (0.14 pmol in 1 µl)
was then added to the extract and incubated at RT for
10 additional min. The DNA-protein complex was resolved by
electrophoresis in a 4% polyacrylamide gel (60:1) run at RT and
10 V/cm for 2-3 hr. Following drying of the gel, radiolabeled
DNA-protein complexes were detected by autoradiography.
Size Estimation of TB-RBP from UV Crosslinking.
We have reported that a protein we have previously called p18, and now
designate TB-RBP, forms an RNA-protein complex with transcript c of
the 3
UTR of mP2 (15, 20). This change in
protein name and estimated size (see below) is based on our previous
incorrect assumption that the RNA component of the UV-crosslinked RNA-protein
complex of about 30 kDa contributed significantly to the
migration of the complex in SDS/PAGE (19).
To more precisely estimate the molecular weight of the protein component of
this RNA-protein complex, we have performed an exhaustive RNase T1
digestion of UV-crosslinked RNA-protein complexes. After UV
crosslinking, we detect transcript c-protein complexes of about
32 kDa with testicular or brain extracts (Fig. 1, lane 1)
(20). Increased
digestion of the UV-crosslinked RNA-protein complexes with RNase T1
(up to 50 units) reduces the molecular weight of the complex
estimated from electrophoresis in a SDS/15% polyacrylamide gel to
about 30 kDa (Fig. 1,
lanes 2 and 3). Since most of the RNA is digested from the
RNA-protein complex under these incubation conditions, we conclude
that the molecular weight of TB-RBP, the protein component of the
RNA-protein complex, is near 30 kDa.
Fig. 1. Saturation digestion of
UV-crosslinked RNA-protein complexes with RNase T1. [32P]-Labeled
transcript c-protein complexes were crosslinked with UV irradiation,
and the complexes were isolated from a native polyacrylamide gel,
subjected to RNase T1 digestion, and resolved in an SDS/15% PAGE.
Lane 1, control UV-crosslinked RNA-protein complex without
RNase T1 digestion. Lanes 2 and 3, UV-crosslinked complex
after digestion with 5 and 50 units of RNase T1, respectively. Arrow
points to the fastest migrating RNA-protein complex obtained after
digestion with 50 units of RNase T1. Sizes of prestained protein
markers are indicated to the right of the gel.
[View Larger
Version of this Image (67K GIF file)]
Purification of TB-RBP.
Based upon the binding affinity between TB-RBP and the Y and H sequence
elements of the 3
UTR of mP2, we have purified TB-RBP to near homogeneity in a
two-step procedure using RNA affinity and DEAE-Sepharose ion
exchange chromatographies. Testicular and brain extracts were passed
over a RNA affinity column constructed with a polyadenylylated
transcript c. After extensive washing, bound proteins were step
eluted with increasing salt and RNA gel shift assays were performed
to detect TB-RBP. The majority of TB-RBP was eluted from the RNA
affinity column in the 0.5 M KCl fraction (Fig. 2A, lane E1).
Small amounts of TB-RBP were observed in the flowthrough, first
wash, and 1.0 M KCl eluted fractions (Fig. 2A, lanes FT,
W1, and E2), and no TB-RBP was detected in the later wash fractions
or the 2.0 M KCl elution fraction (Fig. 2A, lanes W2,
W3, W4, and E3).
Fig. 2. RNA gel retardation assay and
SDS/PAGE analysis of the protein fractions obtained by RNA affinity
chromatography. (A) After dialysis, aliquots (5 µl) of
protein from each purification step were analyzed for RNA binding by
a RNA gel retardation assay using [32P]-labeled
transcript c. The RNA-protein complexes were then resolved in 4%
native polyacrylamide gel. TE, crude testicular extract; FT,
flowthrough fraction; W1-W4, wash fractions; E1-E3, 0.5, 1.0, and
2.0 M KCl step elution fractions, respectively. (B) Aliquots (30 µl)
of the protein fractions analyzed in A were electrophoresed in
SDS/12.5% PAGE and silver stained. Sizes of the prestained protein
markers are indicated at right. Arrow in A indicates the location
of the TB-RBP-transcript c complex in crude extracts. Arrowhead
indicates the RNA-protein complex formed with transcript c and
another testis RNA-binding protein (23).
[View Larger
Version of this Image (48K GIF file)]
To determine the level of purification obtained by the RNA
affinity procedure, we silver stained aliquots of the same RNA affinity
purified protein fractions after electrophoresis in SDS/12.5% polyacrylamide
gels (Fig. 2B).
In contrast to the heterogenous population of proteins in the crude
testicular extract (Fig. 2B, lane
TE), a reduced number of proteins were eluted from the RNA affinity
column after the extensive washes (Fig. 2B, lanes E1,
E2, and E3). A group of proteins of about 25-35 kDa eluted in the
E1 fraction (Fig. 2B,
lane E1), the fraction containing most of the TB-RBP-binding
activity (Fig. 2A,
lane E1). One protein band of about 30 kDa closely matched the
molecular weight of TB-RBP estimated from the RNase T1 digestions
(Figs. 1, lane
3 and 2B, arrow). The absence of RNA-binding activity in
the E2 fraction, which contained a small amount of a similar size
30-kDa protein (Fig. 2B, lane E2),
is likely due to the loss of TB-RBP activity as a result of the
higher salt concentration of the E2 fraction. These data suggest
that after RNA affinity chromatography, TB-RBP is highly enriched in
a fraction that elutes at 0.5 M KCl.
To further purify TB-RBP, DEAE-Sepharose chromatography was used (Fig. 3). RNA gel shift
assays reveal that when the E1 fraction of the RNA affinity column
was loaded onto a DEAE-Sepharose column, the majority of TB-RBP was
step eluted in the 300 mM KCl fraction as previously seen with
crude extracts (15)
(Fig. 3A).
When aliquots of the same protein fractions are silver stained
following electrophoresis in SDS/12.5% polyacrylamide gels, one
predominant protein of about 30 kDa is seen in the 300 mM
KCl fraction (Fig. 3A). Based on
its size, elution, and RNA-binding properties, we conclude that this
protein of about 30 kDa is TB-RBP, the protein that binds to
the 3
UTR of protamine mRNAs (15).
Fig. 3. RNA gel retardation assay and
SDS/PAGE analysis of the protein fractions obtained by DEAE-Sepharose
chromatography. (A) Aliquots (5 µl) of protein from each
purification step were assayed for RNA-protein complex formation as
described in Fig. 2.
E1, fraction E1 from the RNA affinity column of Fig. 2; FT, flowthrough
fraction; 0.04, 0.1, 0.3, 0.5, and 1.0 (M)
represent the concentrations of KCl used for step elution,
respectively. Arrow indicates the TB-RBP-transcript c complex. (B)
Aliquots (30 µl) of the protein fractions analyzed in A
were electrophoresed in SDS/12.5% PAGE and silver stained. The sizes
of the prestained protein markers are indicated at right. Arrow
indicates position of TB-RBP.
[View Larger
Version of this Image (38K GIF file)]
Partial Amino Acid Sequence of TB-RBP.
To facilitate sequence analysis, the proteins in the 300 mM KCl
fraction of the DEAE-Sepharose column were concentrated, resolved in
SDS/12.5% PAGE, and transferred to a polyvinylidene diflouride membrane.
The predicted protein of 30 kDa was visualized by Ponceau S
staining and excised for microsequencing. After trypsin digestion, sequences
were obtained from 2 peptides containing 10 amino acids (Val-Val-Gln-Ser-Leu-Glu-Gln-Thr-Ala-Arg)
and 13 amino acids (Glu-Ala-Val-Thr-Glu-Ile-Leu-Gly-Ile-Glu-Pro-Asp-Arg).
Using the two peptide sequences of TB-RBP, a computer search against
the GENEMBL database revealed that
the two sequenced peptides were identical to amino acids 27-36 and
117-129 of a human DNA-binding protein, translin, proposed to be
associated with chromosomal translocations in lymphoid cells (21).
Isolation of TB-RBP cDNAs.
The complete cDNA encoding TB-RBP was obtained by a combination of screening
two mouse testis cDNA libraries and PCR amplification of the 5
terminus. As reported for translin, the TB-RBP cDNAs encode a
protein of 228 amino acids (including the initiation methionine)
with a molecular weight of 26.2 kDa (21). Although no
common RNA-binding motifs are detected in TB-RBP, a heptad repeat of
hydrophobic amino acids characteristic of a leucine zipper from
amino acids 177-212 and a transmembrane helix from amino acids
93-114 are seen. The mouse TB-RBP shows 90% identity in nucleotide
sequence and 99% amino acid identity to the human protein, translin
(21). The three
amino acids that differ between human translin and mouse TB-RBP at
amino acids 49 (alanine to threonine), 66 (glycine to
serine), and 226 (valine to glycine) represent neutral changes
(Fig. 4, vertical
lines). TB-RBP contains five potential phosphorylation sites for
protein kinase C located at amino acids
34, 67, 84, 190, and 213, (24) and three
potential sites for tyrosine kinase at amino acids
85, 200, and 213 (25). Domains
of TB-RBP also share significant homology to a number of other known
proteins. Amino acids 9-35 and 14-47 of TB-RBP show 62% and 55%
similarity to amino acids 473-499 and 768-801 of a human kinesin
heavy chain, respectively (26). A 44 amino
acid sequence from residues 82-126 exhibits a 51% similarity to amino
acids 18-62 of the human mitochondrial protein, cytochrome c
oxidase polypeptide II (27).
Fig. 4. Amino acid sequence comparison of
TB-RBP and translin. The underlined sequence denotes the putative
leucine-zipper domain. The double underlined sequence denotes the
transmembrane helix. The three amino acids that differ between
TB-RBP and translin are denoted by vertical lines. The amino acid
sequence of mouse TB-RBP is 99% identical to human translin.
[View Larger
Version of this Image (26K GIF file)]
Recombinant TB-RBP Binds to
Single-Stranded DNA Oligonucleotides That Contain Chromosomal Breakpoint
Consensus Sequences.
Recombinant TB-RBP synthesized in E. coli and purified as a GST
fusion protein was used in DNA gel shift assays to confirm that
TB-RBP binds to specific single-stranded DNA sequences. As reported
by Aoki et al. (21),
the recombinant protein binds to the oligonucleotide Bcl-CL1, a
target sequence within the clustered breakpoint region of the Bcl-2
oncogene in follicular lymphoma patients (Fig. 5, lane 1). These
complexes were sequence specific, since complete competition was
seen when unlabeled Bcl-CL1 was used as a competitor (Fig. 5, lanes 5-7),
whereas no significant diminution in DNA-protein complex was seen
with a nonspecific oligonucleotide, MPR2PRI (Fig. 5, lanes 2-4).
Similar DNA-protein complexes were seen with TB-RBP present in
testis and brain extracts (data not shown).
Fig. 5. Recombinant TB-RBP binds to
single-stranded DNA oligonucleotides containing specific chromosomal breakpoint
sequences. Fifty nanograms of recombinant TB-RBP was incubated with
increasing amounts of nonspecific competitor MPR2PRI (5-CTATAGAATTCTCAAGCTTGC-3
)
(lanes 2-4) or specific competitor Bcl-CL1 (lanes 5-7) for 10 min
at RT. [32P]-labeled Bcl-CL1 (0.14 pmol) was then added and
incubated for 10 min. The TB-RBP-DNA complex (arrowhead) was
detected by a mobility shift assay on a 4% polyacrylamide gel.
[View Larger
Version of this Image (51K GIF file)]
When TB-RBP Is Immunodepleted from a
Testicular Extract, No RNA-Protein Complex Is Detected.
To confirm that the RNA-binding protein TB-RBP in crude extracts and
translin are the same protein, antibody prepared against recombinant
TB-RBP was used to immunoprecipitate TB-RBP from testicular extracts,
and RNA gel shifts were performed with transcript c. When RNA gel
shifts were performed with the supernatant from a control
immunoprecipitation in which pre-immune serum was used, no reduction
in the amount of expected RNA-protein complex was seen (Fig. 6A, lane 2).
In contrast, following immunoprecipitation with antiserum to TB-RBP,
no RNA-protein complex was detected (Fig. 6A, lane 3).
This precipitation appears specific since no diminution in the
amount of RNA binding was seen with the mouse germ-cell specific
protein p48/52 present in the same extract (Fig. 6, open arrowhead).
Western blots of the supernatant fractions of the immunoprecipitated
testis extract confirmed that TB-RBP was removed from the
supernatant by immunoprecipitation with the antiserum to TB-RBP
(Fig. 6B,
lane 3). No precipitation was seen with the preimmune serum (Fig. 6B, lane 2).
Western blots of the precipitates confirmed that TB-RBP was
specifically precipitated by its antiserum (data not shown).
Fig. 6. Immunoprecipitation of TB-RBP
inhibits the formation of TB-RBP-RNA complexes. (A) Equal amounts of the
supernatant from testicular cytoplasmic extracts (20 µg)
incubated with TBS (lane 1), pre-immune serum (lane 2), or
anti-TB-RBP antibody (lane 3) were incubated with [32P]-labeled
transcript c and the RNA-protein complexes were resolved on 4%
native polyacrylamide gels. The TB-RBP-RNA complex is indicated by a
solid arrowhead. The p48/52-RNA complex is indicated by an open
arrowhead. (B) Western blot assays. Equal volumes (14 µl) of
the supernatants used in A were resolved on an SDS/10% polyacrylamide
gel, transferred to a nitrocellulose filter, and TB-RBP was detected
with antibody against a TB-RBP peptide. TB-RBP is indicated by a
solid arrowhead.
[View Larger
Version of this Image (70K GIF file)]
We have purified TB-RBP, an RNA-binding protein in testis and brain, whose
binding specificities and cellular locations have suggested a
cytoplasmic involvement in translational control and cellular
transport of specific mRNAs (15, 16, 19, 20). Based
on the amino acid sequence predicted from cDNAs encoding TB-RBP, we
conclude that mouse TB-RBP and the human DNA-binding protein,
translin, are about 90% similar at the nucleotide level and nearly
identical (differing in 3 amino acids out of 228) at the amino
acid level. Translin is proposed to function as a DNA-binding protein
that binds to specific DNA sequences at breakpoint junctions of
chromosomal translocations of lymphoid malignancies (21). The
DNA-binding ability of translin is dependent upon the formation of a
multimeric structure (21)
probably mediated through the leucine zipper in the carboxyl
terminus. The leucine zipper may also play an important role for
protein-protein interactions of TB-RBP in the cytoplasm as has been
shown for a LINE 1 RNA-binding protein (28). TB-RBP also
contains a putative transmembrane helix at amino acids 93-114, which
could facilitate interactions between TB-RBP and microtubule
proteins (16).
Although not common, there is a good precedent for germ-cell nucleic
acid-binding proteins that bind both DNA and RNA. Proteins such as
the Xenopus 5S RNA-binding protein (29), the Xenopus
FRG Y2/p54/p56 proteins (30-32), and the
mouse germ-cell specific homologue to FRG Y2/p54/p56 (23, 33) all possess both
RNA- and DNA-binding activities. It has been proposed that translin
recognizes two types of DNA target sequences: a combination of the
consensus sequences ATGCAG and GCCC [A/T] [G/C] [G/C] [A/T] or a
tandem repeat of GCCC [A/T] [G/C] [G/C] [A/T] with gaps of a few
nucleotides intervening (21). As reported by
Aoki et al. (21), we have
confirmed that Bcl-CL1, a single-stranded DNA oligonucleotide from a
clustered breakpoint in the Bcl-2 oncogene in lymphoma patients,
specifically binds recombinant TB-RBP (Fig. 5) and TB-RBP in
testis and brain extracts (data not shown), whereas one of the
reported nonspecific DNA sequences does not (Fig. 5). The
TB-RBP-binding sites in many translationally regulated testicular mRNAs
such as protamine 1 and 2 and transition protein 1 and brain
mRNAs such as tau and myelin basic protein recognize RNA sequences similar
to the DNA-binding consensus sequences identified for translin (15, 16). Since translin
is abundant in the cytoplasm of many cell lines while its nuclear
location has been restricted to lymphoid cell lines with rearranged
Ig and T cell antigen receptor loci, translin may also have
additional cytoplasmic functions in lymphoid and nonlymphoid cells.
The absence of common RNA recognition motifs in TB-RBP sets it apart from
many RNA-binding proteins (34). However,
RNA-binding proteins, such as the human teratocarcinoma protein p40,
which binds to LINE-1 RNA (28), an AU-rich
sequence-binding protein (35), thymidylate
synthase (36),
and one of the iron responsive element-binding proteins (IRE-BP1) (37), all lack common
RNA-binding domains. Some of these RNA-binding proteins perform
additional functions, i.e., IRE-BP1 possesses aconitase activity (38) and the
AU-rich sequence-binding protein has enoyl-CoA hydratase activity (35). Although we do
not know whether TB-RBP has any enzymatic activity, it shows
significant homology to a mitochondrial cytochrome c oxidase
polypeptide II and to a kinesin heavy chain protein. Interestingly,
cytochrome c oxidase, the kinesin heavy chain, and the
mitochondrial enoyl-CoA hydratase all bind to components of the
cytoskeleton as shown "in vitro" for TB-RBP (16). It is
likely that TB-RBP interacts with kinesin-type motor molecules as it
transports mRNAs along microtubules.
The identity between TB-RBP and translin suggests an apparent contradiction
between the widespread expression of translin in somatic tissues (21) and our reports
of TB-RBP RNA-binding activity being restricted to testis and brain
(20). Using RNA
gel shift assays, we have detected TB-RBP in extracts of brain and
testis but not in extracts of spleen, kidney, liver, lung, or heart
(20). In fact,
TB-RBP mRNAs and DNA-binding activities are widely expressed in
somatic tissues and recombinant translin can bind to a wide range of
single-stranded DNA junction sequences (ref. 21, X.-Q.W. and
N.B.H., unpublished work). We propose that posttranslational
modifications of TB-RBP in specific tissues such as testis and brain
allow TB-RBP to selectively bind RNA.
The activities of many proteins are regulated by kinases and phosphatases.
For instance, phosphorylation of a 60-kDa Xenopus oocyte
RNA-binding protein suppresses assembly of mRNPs (39) and
phosphorylation modifies the RNA binding of an 82-kDa clam oocyte
protein, thereby activating masked mRNAs (9). Although treatment
of testicular extracts with potato acid-phosphatase abolishes the
RNA-binding activity of TB-RBP (15), we do not know
that this is solely a direct effect. In fact, recombinant TB-RBP
expressed in E. coli can bind RNA (X.-Q.W. and N.B.H., unpublished
data), suggesting that phosphorylation of TB-RBP may change its
binding specificity. Preliminary data indicate that the nucleic
acid-binding properties of TB-RBP vary, dependent upon their
cellular location and developmental stage (X.-Q.W. and N.B.H.,
unpublished data). The testis and brain enzymes involved in the
activation/deactivation of TB-RBP have yet to be identified. It will
be important to determine whether the translins present in the
cytosol and nuclei of lymphoid cell lines also undergo posttranslational
modifications and how nuclear and cytoplasmic translins differ.
In conclusion, we have purified a protein and cloned the mouse cDNA of a
highly conserved protein, TB-RBP/translin. In the cytosol,
TB-RBP/translin has been proposed to translationally regulate stored
mRNAs during spermiogenesis and facilitate transport of specific
mRNAs in the nervous system (15, 16). TB-RBP/translin
also binds to specific conserved DNA sequences often involved in
chromosomal translocations in lymphoid cells (21). Based upon
the specificity of translin binding to consensus sequences of
breakpoints in chromosome translocations, we propose that in the
testis TB-RBP functions in the nuclei of germ cells in meiotic recombination
or DNA repair in addition to serving as an RNA- and
microtubule-binding protein in the cytoplasm of testicular cells.